Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) agreed to engage China Resources Kelun as a downstream distributor and seller for some of its commercialized products from time to time during Oct. 31, 2024, and Dec. 31, 2025, a Thursday Hong Kong bourse filing said.
Under the agreement, the company will sell its commercialized products to the other party from time to time, which the other party will distribute downstream or sell directly to the consumers.
The annual caps set for the transactions are 10 million yuan for 2024 and 15 million yuan for 2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。